Nkarta Inc (NKTX)

May 22, 2026

Nkarta Inc. (NKTX) Holds Steady at $3.03 as Market Awaits CatalystATR Stop - Newser

May 22, 2026

May 21, 2026

Nkarta (NKTX) Posts Record Q1 2026 — EPS $-0.37 Blows Past EstimatesRising Community Picks - newser.com

May 21, 2026

May 19, 2026

NEA (NKTX) drops below 5% ownership in latest Schedule 13D/A filing - Stock Titan

May 19, 2026

May 15, 2026

Nkarta Insider Stock Sellers Must Be Relieved As Market Cap Falls To US$201m - simplywall.st

May 15, 2026

May 14, 2026

Here's Why We're Not Too Worried About Nkarta's (NASDAQ:NKTX) Cash Burn Situation - Yahoo Finance

May 14, 2026

May 13, 2026

Nkarta Price Target Maintained With a $11.00/Share by Needham - Moomoo

May 13, 2026

May 13, 2026

Nkarta, Inc. Stock 12‑Month Price Target Raised to $11.8, Implies 260% Upside - TradingView

May 13, 2026

May 12, 2026

Nkarta (NASDAQ:NKTX) Q1 2026 Narrower Loss Beats Estimates as Autoimmune Trial Advances - ChartMill

May 12, 2026

May 12, 2026

Nkarta (NASDAQ: NKTX) Q1 2026 loss narrows as cash reaches $266.7M - Stock Titan

May 12, 2026

May 12, 2026

Nkarta Inc reports results for the quarter ended March 31Earnings Summary - TradingView

May 12, 2026

May 12, 2026

Nkarta, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com

May 12, 2026

May 12, 2026

Kyverna Therapeutics Announces Initiation of Rolling SPS BLA Submission and Reports First Quarter 2026 Financial Results - Weekly Voice

May 12, 2026

May 12, 2026

Nkarta (NKTX) Q1 2026 results: NKX019 trial progress and cash runway into 2029 - Stock Titan

May 12, 2026

May 12, 2026

Nkarta Reports First Quarter 2026 Financial Results and Corporate Highlights - The Manila Times

May 12, 2026

May 12, 2026

FDA deal lets Nkarta test autoimmune cell therapy in community clinics - Stock Titan

May 12, 2026

May 11, 2026

TradingKey - TradingKey

May 11, 2026

May 08, 2026

How Nkarta (NKTX) performance compares to expectations (Momentum Fading) 2026-05-08Social Buzz - newser.com

May 08, 2026

May 01, 2026

NKTX stock up on upbeat regulatory update on lead autoimmune program - MSN

May 01, 2026

May 01, 2026

Nkarta, Inc. (NASDAQ:NKTX) Given Average Rating of "Hold" by Analysts - MarketBeat

May 01, 2026

Apr 30, 2026

NKTX Q1'26 Earnings: revenue estimate is 0 USD - TradingView

Apr 30, 2026

Apr 29, 2026

NKTX Nkarta reports wider than expected Q4 2025 loss, shares fall nearly 3% on weak investor sentiment.AI Stock Signals - Newser

Apr 29, 2026

Apr 28, 2026

Nkarta (NASDAQ:NKTX) Stock Price Down 3.1%Here's Why - MarketBeat

Apr 28, 2026

Apr 23, 2026

[ARS] Nkarta, Inc. SEC Filing - Stock Titan

Apr 23, 2026

Apr 23, 2026

Executive pay, auditor and board elections on ballot at Nkarta (NKTX) 2026 virtual meeting - Stock Titan

Apr 23, 2026

Apr 22, 2026

NKTX (Nkarta Inc.) reports wider than expected Q4 2025 loss, shares jump nearly 16 percent on upbeat investor sentiment.Retail Trader Ideas - Cổng thông tin điện tử Tỉnh Sơn La

Apr 22, 2026

Apr 20, 2026

Nkarta cell therapy trial may soon offer outpatient treatment option in AAV - ANCA Vasculitis News

Apr 20, 2026

Apr 20, 2026

Nkarta (NKTX) Stock Dividend Safety (Underperforming) 2026-04-20Crowd Trend Signals - Xã Thanh Hà

Apr 20, 2026

Apr 18, 2026

Nkarta (NKTX) Stock: Why It Could Change (In Focus) 2026-04-18Professional Trade Ideas - Cổng thông tin điện tử tỉnh Lào Cai

Apr 18, 2026

Apr 18, 2026

Nkarta (NKTX) Stock: Is It Stabilizing (In Focus) 2026-04-18Trend Following Picks - Newser

Apr 18, 2026

Apr 17, 2026

NKTX Stock Up on Upbeat Regulatory Update on Lead Autoimmune Program - The Globe and Mail

Apr 17, 2026

Apr 17, 2026

Nkarta receives FDA agreement for outpatient NKX019 dosing By Investing.com - Investing.com India

Apr 17, 2026

Apr 17, 2026

Should I buy Nkarta (NKTX) - Zacks Investment Research

Apr 17, 2026

Apr 16, 2026

Stifel Maintains Nkarta(NKTX.US) With Buy Rating, Maintains Target Price $11 - Moomoo

Apr 16, 2026

Apr 16, 2026

Nkarta wins FDA nod for new trial protocol (NKTX:NASDAQ) - Seeking Alpha

Apr 16, 2026

Apr 16, 2026

symbol__ Stock Quote Price and Forecast - CNN

Apr 16, 2026

Apr 16, 2026

Needham Maintains Nkarta(NKTX.US) With Buy Rating, Maintains Target Price $11 - Moomoo

Apr 16, 2026

Apr 16, 2026

Nkarta Announces FDA Agreement on Outpatient Dosing of NKX019 in Autoimmune Disease, Expanding Access to Community Rheumatology Centers - Sahm

Apr 16, 2026

Apr 15, 2026

NKTX: Pivot to off-the-shelf CAR-NK therapy in autoimmune diseases, with broad trials and strong cash runway - TradingView

Apr 15, 2026

Apr 15, 2026

Nkarta announces FDA agreement on outpatient dosing of NKX019 in autoimmune disease, expanding access to community rheumatology centers - marketscreener.com

Apr 15, 2026

Apr 15, 2026

Nkarta receives FDA agreement for outpatient NKX019 dosing - Investing.com

Apr 15, 2026

Apr 15, 2026

Nkarta Reports FDA Agreement on Outpatient Dosing of NKX019 - marketscreener.com

Apr 15, 2026

Apr 15, 2026

Nkarta targets 2-hour monitoring, not overnight stays, in cell therapy trials - Stock Titan

Apr 15, 2026

Apr 13, 2026

CEO Moves: Will Nkarta Inc stock benefit from M A2026 Investor Takeaways & Technical Pattern Alert System - baoquankhu1.vn

Apr 13, 2026

Apr 11, 2026

If You Invested $1,000 in Nkarta, Inc. (NKTX) - Stock Titan

Apr 11, 2026

Apr 10, 2026

Aug PostEarnings: Is Nkarta Inc stock suitable for long term investing2026 Big Picture & Free AI Powered Buy and Sell Recommendations - baoquankhu1.vn

Apr 10, 2026

Apr 09, 2026

Nkarta to Participate in Needham Virtual Healthcare Conference - Bitget

Apr 09, 2026

Apr 09, 2026

Nkarta leaders to discuss autoimmune cell therapy at Needham event - Stock Titan

Apr 09, 2026

Apr 07, 2026

Ideas Watch: Does Nkarta Inc have declining or rising EPSGap Down & High Win Rate Trade Tips - baoquankhu1.vn

Apr 07, 2026

Apr 06, 2026

Idiopathic Membranous Nephropathy Market is Predicted to Reach USD 1 Billion by 2036 Due to Rising Therapeutic Options | DelveInsight - GlobeNewswire Inc.

Apr 06, 2026